Table 1.

Patient Demographics for flow cytometric validation.

Patient #	Age	Sex	AML subtype	Recurrent Genetic Abnormalities	Cell Source
1	41	F	M4	FLT3-ITD, NPM1c, c-Kit	BM
2	61	M	M4	FLT3-ITD, NPM1c	BM
3	33	M	M3	PML/RARA	BM
4	55	M	AML-MRC	NPM1c, CEBPA	BM
5	70	M	AML-MRC	NRAS, SF3B1, ETV6	BM
6	65	M	M2	None were identified	BM
7	73	M	M2	Tet2	BM
8	42	M	M2	FLT3-ITD, c-Kit	BM
9	33	F	M5	None were identified	BM
10	84	F	M1	IDH1	BM
11	51	M	M0	None were identified	BM
12	49	M	M2	FLT3-ITD, c-Kit	PB
13	71	M	M4	None were identified	BM
14	76	M	AML-MRC	None were identified	BM
15	74	M	M4	NPM1c	PB
16	14	M	M4	None were identified	BM
17	NA	NA	NA	NA	BM

AML-MRC, AML with myelodysplasia related changes; BM, Bone marrow; PB, Peripheral Blood; NA, Data not available.